Los Angeles Capital Management’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$174K Sell
8,221
-60
-0.7% -$1.28K ﹤0.01% 1204
2026
Q1
$181K Sell
8,281
-51,136
-86% -$1.14M ﹤0.01% 1172
2025
Q4
$949K Sell
59,417
-27,685
-32% -$486K ﹤0.01% 643
2025
Q3
$1.02M Buy
87,102
+45,245
+108% +$450K ﹤0.01% 702
2025
Q2
$389K Buy
41,857
+6,009
+17% +$49.3K ﹤0.01% 954
2025
Q1
$241K Buy
35,848
+127
+0.4% +$1.22K ﹤0.01% 962
2024
Q4
$379K Buy
+35,721
New +$432K ﹤0.01% 878

Other funds holding IMNM

Los Angeles Capital Management's IMNM Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Immunome (IMNM) stake by 0.72% in Q2 2026, selling an estimated $1.28K and leaving 8,221 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1204.

Los Angeles Capital Management first reported a position in IMNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.02M in Q3 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Los Angeles Capital Management held 8,221 shares of Immunome worth $174K as of Q2 2026.
  • Los Angeles Capital Management sold 60 Immunome shares in Q2 2026, an estimated $1.28K.
  • Immunome made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1204 holding.
  • Los Angeles Capital Management first reported a position in Immunome in Q4 2024 and has held it in 7 quarters since.
  • Los Angeles Capital Management's Immunome position peaked at $1.02M in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.